Yisheng Biopharma Co., Ltd.

Founded in 1994 and based in Beijing, China, Yisheng Biopharma operates as a biopharmaceutical company. The company was founded by Chairman Zhang Yi. Yisheng Biopharma raised USD 130 million in Series B funding co-led by Oceanpine Capital and OrbiMed Advisors, with participation from other investors. Yisheng Biopharma is engaged in discovering and developing biotherapeutics for cancers and infectious diseases using novel PIKA® immunomodulating technology.

Yisheng Biopharma’s YSJA™ rabies vaccine is an alum-free lyophilized rabies vaccine that has been commercialized in China and has served over 16 million patients for post-exposure protection against rabies. The company offers other products in clinical development that include YS-ON-001, for the treatment of solid tumors, YS-HBV-001 for hepatitis B, and PIKA YS-SC2-010, a prophylactic and therapeutic vaccine candidate against the Covid-19 virus. PIKA YS-HBV-002 for chronic HBV and PIKA YS-ON-002 for solid tumors, and among other products that are candidates in preclinical and discovery stages. Yisheng Biopharma plans to support the expansion of the company’s research and development center, accelerate commercialization strategies including the clinical development of multiple vaccine candidates, and the construction of biologics production facilities in China and Singapore.